Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 5(58), p. 2921-2924, 2014

DOI: 10.1128/aac.02482-13

Links

Tools

Export citation

Search in Google Scholar

Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Orange circle
Published version: archiving restricted
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT In this study, oritavancin had modal MIC, MIC 50 , and MIC 90 values of 0.03, 0.03, and 0.06 μg/ml, respectively, against Staphylococcus aureus . Similar results (MIC 50/90 , 0.03/0.06 μg/ml) were observed against methicillin-resistant and -susceptible isolates and those demonstrating multidrug-resistant (MDR) and non-MDR phenotypes. When oritavancin (MIC 50/90 , 0.06/0.12 mg/ml) was tested against S. aureus with elevated MIC values for daptomycin (i.e., 1 to 4 mg/ml) and vancomycin (i.e., 2 mg/ml), it showed MIC results 2-fold higher than those for the more susceptible vancomycin or daptomycin counterparts (MIC 50/90 , 0.03/0.06 mg/ml), yet it inhibited these isolates at ≤0.25 mg/ml.